Switch theme
Sign up to access all valuation multiples
Inventionmed SA focuses on the development of medical simulators based on VR technology for use in education in esthetic and clinical dermatology. The firm's flagship project consists of TutorDerm, a simulator and an application that allow performing the activities necessary to treat specific dermatological conditions.
2009
3
Last FY Revenue $0.1M
Last FY EBITDA -$0.4M
$10.8M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
In the most recent fiscal year, Inventionmed achieved revenue of $0.1M and an EBITDA of -$0.4M.
Inventionmed expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Inventionmed valuation multiples based on analyst estimates| NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|
| Revenue | XXX | $0.1M | XXX | XXX | XXX |
| Gross Profit | XXX | $26K | XXX | XXX | XXX |
| Gross Margin | XXX | 35% | XXX | XXX | XXX |
| EBITDA | XXX | -$0.4M | XXX | XXX | XXX |
| EBITDA Margin | XXX | -583% | XXX | XXX | XXX |
| EBIT | XXX | -$0.7M | XXX | XXX | XXX |
| EBIT Margin | XXX | -889% | XXX | XXX | XXX |
| Net Profit | XXX | -$1.1M | XXX | XXX | XXX |
| Net Margin | XXX | -1441% | XXX | XXX | XXX |
| Net Debt | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Inventionmed's stock price is PLN 0 (or $0).
Inventionmed has current market cap of PLN 37.5M (or $9.9M), and EV of PLN 40.8M (or $10.8M).
See Inventionmed trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $10.8M | $9.9M | XXX | XXX | XXX | XXX | n/a |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Inventionmed has market cap of $9.9M and EV of $10.8M.
Inventionmed's trades at 146.7x EV/Revenue multiple, and -25.2x EV/EBITDA.
Equity research analysts estimate Inventionmed's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Inventionmed's P/E ratio is not available.
See valuation multiples for Inventionmed and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $9.9M | XXX | $9.9M | XXX | XXX | XXX |
| EV (current) | $10.8M | XXX | $10.8M | XXX | XXX | XXX |
| EV/Revenue | n/a | XXX | 146.7x | XXX | XXX | XXX |
| EV/EBITDA | n/a | XXX | -25.2x | XXX | XXX | XXX |
| EV/EBIT | n/a | XXX | -16.5x | XXX | XXX | XXX |
| EV/Gross Profit | n/a | XXX | n/a | XXX | XXX | XXX |
| P/E | n/a | XXX | -9.4x | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | 58.6x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialInventionmed's revenue per employee in the last FY averaged $25K, while opex per employee averaged $0.2M for the same period.
Inventionmed's rule of 40 is unknown (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Inventionmed's rule of X is unknown (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Inventionmed and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | n/a | XXX | n/a | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | -583% | XXX | XXX | XXX |
| EBITDA Growth | n/a | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | n/a | XXX | n/a | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | n/a | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $25K | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.2M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 924% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Philips | XXX | XXX | XXX | XXX | XXX | XXX |
| Perspective Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| SmartVest | XXX | XXX | XXX | XXX | XXX | XXX |
| InfuSystem | XXX | XXX | XXX | XXX | XXX | XXX |
| Myomo | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Inventionmed acquired XXX companies to date.
Last acquisition by Inventionmed was XXXXXXXX, XXXXX XXXXX XXXXXX . Inventionmed acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Inventionmed founded? | Inventionmed was founded in 2009. |
| Where is Inventionmed headquartered? | Inventionmed is headquartered in Poland. |
| How many employees does Inventionmed have? | As of today, Inventionmed has 3 employees. |
| Is Inventionmed publicy listed? | Yes, Inventionmed is a public company listed on WAR. |
| What is the stock symbol of Inventionmed? | Inventionmed trades under INM ticker. |
| When did Inventionmed go public? | Inventionmed went public in 2013. |
| Who are competitors of Inventionmed? | Similar companies to Inventionmed include e.g. Philips, Perspective Therapeutics, SmartVest, InfuSystem. |
| What is the current market cap of Inventionmed? | Inventionmed's current market cap is $9.9M |
| Is Inventionmed profitable? | Yes, Inventionmed is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
